The Diagnostic Performance of Maximum Uptake Value and Apparent Diffusion Coefficient in Differentiating Benign and Malignant Ovarian or Adnexal Masses: A Meta-Analysis

Abstract

ObjectiveThe purpose of this meta-analysis was to provide evidence for using maximum uptake value (SUVmax) and apparent diffusion coefficient (ADC) to quantitatively differentiate benign and malignant ovarian or adnexal masses, and to indirectly compare their diagnostic performance.Material and MethodsThe association between SUVmax, ADC and ovarian or adnexal benign and malignant masses was searched in PubMed, Cochrane Library, and Embase databases until October 1, 2021. Two authors independently extracted the data. Studies included in the analysis were required to provide data for the construction of a 2 × 2 contingency table to evaluate the diagnostic performance of SUVmax or ADC in differentiating benign and malignant ovarian or adnexal masses. The quality of the enrolled studies was evaluated by Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) instrument, and the meta-analysis was conducted using Stata software version 14.0. Forest plots were generated according to the sensitivity and specificity of SUVmax and ADC, and meta-regression analysis was further used to assess heterogeneity between studies.ResultsA total of 14 studies were finally included in this meta-analysis by gradually excluding duplicate literatures, conference abstracts, guidelines, reviews, case reports, animal studies and so on. The pooled sensitivity and specificity of SUVmax for quantitative differentiation of benign and malignant ovarian or adnexal masses were 0.88 and 0.89, respectively, and the pooled sensitivity and specificity for ADC were 0.87 and 0.80, respectively.ConclusionQuantitative SUVmax and ADC values have good diagnostic performance in differentiating benign and malignant ovarian or adnexal masses, and SUVmax has higher accuracy than ADC. Future prospective studies with large sample sizes are needed for the analysis of the role of SUVmax and ADC in the differentiation of benign and malignant ovarian or adnexal masses.

Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer

“…Fluorodeoxyglucose (FDG) labeled with radionuclide 18 F is widely used in clinical practice and has been proved to be highly accurate in the differential diagnosis of benign and malignant ovarian masses ( 128 , 129 ). However, a study of 18 F-FDG PET/CT to evaluate the expression status of HER2 receptor has not been reported.…”

18F-FDG PET/CT features of Meigs syndrome induced by ovarian sex cord stromal tumors: a retrospective clinical study

“…Furthermore, a subsequent quantitative investigation evaluating benign and malignant ovarian tumors through the PET/CT parameter SUVmax demonstrated similarly robust diagnostic performance. This analysis revealed that the SUVmax of benign and malignant ovarian tumors averaged 2.2 and 9.6, respectively 18 . The findings of our present study substantiate these previous research outcomes by highlighting a significant disparity in 18 F-FDG uptake between the MS and OC-PMS groups.…”

18F-FDG PET/CT metabolic parameters can semi-quantitatively evaluate the nature of the heart and pericardial masses: a retrospective study

“…18 F-FDG PET/CT, which integrates morphological and metabolic function information, has been widely used in the diagnosis, preoperative staging, treatment and prognosis assessment of tumors, and has shown higher clinical application value than traditional imaging methods in the management of tumors 8 , 9 . The maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), total lesion glycolysis (TLG), tumor metabolic volume (MTV), the maximum tumor-to-mediastinum (blood pool of descending aorta) background ratio (TMR) and the maximum tumor-to-liver background ratio (TLR) as important metabolic parameters in PET/CT, have shown high diagnostic value in the differentiation of benign and malignant tumors 10 – 12 . Due to the rarity of cardiac tumors, there is currently limited research on the diagnosis and differentiation of cardiac tumors through PET/CT 13 – 15 .…”